Stop STALLING Act

Hozzl · 2025-04-15T04:23:15Z

Explore the details of Senate Bill 1095 Stop STALLING Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

4/15/2025, 4:23 AM

Summary of Bill S 1095

Bill 119 s 1095, also known as the "Sham Citizen Petition Deterrence Act," aims to empower the Federal Trade Commission (FTC) to prevent the misuse of citizen petitions in the pharmaceutical industry. The bill specifically targets the practice of filing sham citizen petitions as a way to delay the approval of generic drugs or biosimilars and stifle competition.

The main goal of the bill is to promote competition in the pharmaceutical market and ensure that legitimate public health concerns are addressed in a timely manner. By deterring the filing of sham citizen petitions, the FTC can facilitate the efficient review of petitions that are filed in good faith and genuinely raise important public health issues.

Overall, Bill 119 s 1095 seeks to protect consumers by preventing anti-competitive practices in the pharmaceutical industry and promoting a fair and transparent review process for citizen petitions. It aims to strike a balance between fostering competition and safeguarding public health concerns.

Congressional Summary of S 1095

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1095

Bill S 1095 is currently in the status of Bill Introduced since March 24, 2025. Bill S 1095 was introduced during Congress 119 and was introduced to the Senate on March 24, 2025. Bill S 1095's most recent activity was Placed on Senate Legislative Calendar under General Orders. Calendar No. 45. as of April 10, 2025

Bipartisan Support of Bill S 1095

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1095

Primary Policy Focus

Health

Potential Impact Areas

- Administrative remedies

- Business ethics

- Civil actions and liability

- Competition and antitrust

- Department of Health and Human Services

- Drug safety, medical device, and laboratory regulation

- Food and Drug Administration (FDA)

- Licensing and registrations

- Prescription drugs

- Public participation and lobbying

Alternate Title(s) of Bill S 1095

A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.

Comments

Stevie Rodriguez

696

10 months ago

Ugh, this bill is such a joke. Why are they even wasting time on this crap? It's just gonna make things worse for all of us. Can someone explain what the heck is going on with this mess? #SMH